Financial Reports
Related Searches:
Filter by:
February 5, 2009
Pharmaceutical sales in the quarter were $9.3 billion (-9%) and $37.7 billion for the year (-2%). Advair sales were $2.8 billion in the quarter (+47%) and $10.8 billion for the year (+54%).
Read More »
February 4, 2009
Total sales were up 6% in local currencies (-1% in Swiss francs; +10% in U.S. dollars), with the Pharmaceuticals Division representing 79% of group sales and the Diagnostics Division contributing 21%, compensating for the decline in Tamiflu pandemic sales
Read More »
February 3, 2009
Sales of Remicade were $491 million in the quarter (+8%) and $2.1 billion for the year (+28%).
Read More »
February 3, 2009
Singulair sales were $1.1 billion in the quarter (-3%) and $4.3 billion for the year (+2%).
Read More »
January 29, 2009
Nexium sales were $1.3 billion in the quarter (+6%) but down 2% for the year to $5.2 billion. Losec/Prilosec sales were down 11% to $264 million in the quarter and down 14% to $1.1 billion for the year due to generic competition.
Read More »
January 29, 2009
Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve sales collectively grew 10% to $1.9 billion and accounted for 37% of total sales, compared with 33% in 4Q07.
Read More »
January 28, 2009
Pharmaceutical sales were $6.4 billion in the quarter (+5%) and $26.3 billion for the year (+10%), driven by growth in oncology, the cardiovascular portfolio and $2.9 billion of contributions from recently launched products including Aclasta/Reclast, Tekt
Read More »
January 28, 2009
Product sales increased 35% to a record $1.4 billion in the quarter and for the year product sales were up 36% to $5.08 billion, driven primarily by Gilead’s antiviral franchise, and growth in sales of Atripla and Truvada.
Read More »
January 27, 2009
Pharmaceutical sales were $4.5 billion in the quarter (+4%). U.S. pharmaceutical sales were up 13% to $2.8 billion, while international sales were down 9% to $1.7 billion, primarily due to an 8% unfavorable foreign exchange impact.
Read More »
January 27, 2009
Consolidated service revenue for the quarter was $200.9 million in Clinical Research Services (CRS), $31.9 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $43.0 million in Perceptive Informatics, Inc.
Read More »
January 27, 2009
Product sales were up 2% to $3.7 billion in the quarter. Sales in the U.S. were up 1%, to $2.9 billion, while international sales increased 4% to $774 million.
Read More »
January 26, 2009
Wyeth 4Q08
4Q Revenues: $5.3 billion (-7%)
4Q Earnings: $960 million (-5%)
FY Revenues: $22.8 billion (+2%)
FY Earnings: $4.4 billion (-2%)
Comments: Revenues dropped as Effexor sales fell 7% to $902 million in 4Q08. For the year, Effe…
Read More »
January 26, 2009
Pfizer 4Q08
4Q Revenues: $12.3 billion (-4%)
4Q Earnings: $266 million (-96%)
FY Revenues: $48.3 billion (flat)
FY Earnings: $8.1 billion (flat)
Comments: Generic losses continued to dent Pfizer's sales: Zyrtec, Camptosar and Norvasc r…
Read More »
January 21, 2009
Abbott
4Q Revenues: $8.0 billion (+10%)
4Q Earnings: $1.5 billion (+28%)
FY Revenues: $30.0 billion (+14%)
FY Earnings: $4.9 billion (+35%)
Comments: Worldwide pharmaceutical sales were up 10% to $4.6 billion in the quarter, and…
Read More »
January 20, 2009
Johnson & Johnson
4Q Revenues: $15.2 billion (-5%)
4Q Earnings: $2.7 billion (+13%)
FY Revenues: $63.7 billion (+4%)
FY Earnings: $12.9 billion (+22%)
Comments: Pharmaceutical sales were $5.7 billion in the quarter (-11%) and $24.6…
Read More »
